Bayram Catak, F. Et Al. 2024. Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease. Journal of Allergy and Clinical Immunology .

Bayram Catak, F., Catak, M. C., Babayeva, R., Toubia, J., Warnock, N. I., Celmeli, F., ... Hafizoglu, D.(2024). Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease. Journal of Allergy and Clinical Immunology .

Bayram Catak, Feyza Et Al. "Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease," Journal of Allergy and Clinical Immunology , 2024

Bayram Catak, Feyza B. Et Al. "Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease." Journal of Allergy and Clinical Immunology , 2024

Bayram Catak, F. Et Al. (2024) . "Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease." Journal of Allergy and Clinical Immunology .

@article{article, author={Feyza Bayram Catak Et Al. }, title={Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease}, journal={Journal of Allergy and Clinical Immunology}, year=2024}